|
PL2155788T3
(pl)
*
|
2007-04-03 |
2013-02-28 |
Amgen Res Munich Gmbh |
Swoiste międzygatunkowe bispecyficzne czynniki wiążące
|
|
US12492253B1
(en)
*
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
TWI736437B
(zh)
|
2010-11-30 |
2021-08-11 |
日商中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
WO2013096221A1
(en)
*
|
2011-12-21 |
2013-06-27 |
Amgen Inc. |
Variant fc-polypeptides with enhanced binding to the neonatal fc receptor
|
|
BR112015000798A2
(pt)
*
|
2012-07-13 |
2017-06-27 |
Zymeworks Inc |
heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
|
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
WO2014151910A1
(en)
*
|
2013-03-15 |
2014-09-25 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
DK2992020T3
(da)
|
2013-05-03 |
2020-02-10 |
Ohio State Innovation Foundation |
Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller
|
|
LT3074424T
(lt)
|
2013-11-27 |
2025-05-26 |
Zymeworks Bc Inc. |
Bispecifiniai antigeną surišantys konstruktai, nukreipti į her2
|
|
HUE050159T2
(hu)
|
2013-12-17 |
2020-11-30 |
Genentech Inc |
Anti-CD3 antitestek és alkalmazási eljárások
|
|
MX380176B
(es)
|
2014-04-07 |
2025-03-12 |
Chugai Pharmaceutical Co Ltd |
Molecula ligada a antigeno inmunoactivada.
|
|
KR20170017916A
(ko)
*
|
2014-05-13 |
2017-02-15 |
추가이 세이야쿠 가부시키가이샤 |
면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자
|
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
ES2743809T3
(es)
|
2014-07-31 |
2020-02-20 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
|
|
EP3197916A2
(en)
*
|
2014-09-25 |
2017-08-02 |
Amgen Inc. |
Protease-activatable bispecific proteins
|
|
US11566082B2
(en)
|
2014-11-17 |
2023-01-31 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
|
ES2808853T3
(es)
|
2014-11-20 |
2021-03-02 |
Hoffmann La Roche |
Cadenas ligeras comunes y procedimientos de uso
|
|
SG11201704056XA
(en)
|
2014-11-20 |
2017-06-29 |
Hoffmann La Roche |
Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
|
|
RS61010B1
(sr)
|
2014-11-20 |
2020-11-30 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
|
|
CN107530424A
(zh)
*
|
2015-02-20 |
2018-01-02 |
俄亥俄州国家创新基金会 |
针对nkg2d和肿瘤相关抗原的二价抗体
|
|
CN108367057B
(zh)
|
2015-04-06 |
2022-11-22 |
赛通免疫股份有限公司 |
用于胶质母细胞瘤的egfr导向的car疗法
|
|
PL3283524T3
(pl)
|
2015-04-17 |
2023-06-12 |
Amgen Research (Munich) Gmbh |
Konstrukty biswoistego przeciwciała dla cdh3 i cd3
|
|
EP3778640A1
(en)
*
|
2015-05-01 |
2021-02-17 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
|
JP6841754B2
(ja)
*
|
2015-05-13 |
2021-03-10 |
中外製薬株式会社 |
多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
|
|
EP3297672B1
(en)
|
2015-05-21 |
2021-09-01 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
WO2017011414A1
(en)
*
|
2015-07-10 |
2017-01-19 |
Duke University |
Bispecific molecules comprising an hiv-1 envelope targeting arm
|
|
WO2017011413A1
(en)
*
|
2015-07-10 |
2017-01-19 |
Duke University |
Bispecific molecules comprising an hiv-1 envelope targeting arm
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
|
JP2018523686A
(ja)
*
|
2015-08-17 |
2018-08-23 |
マクロジェニクス，インコーポレーテッド |
Ｂ７‐ｈ３及びｃｄ３に結合できる二重特異性１価ダイアボディ並びにその使用
|
|
WO2017055388A2
(en)
*
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
|
JP7044700B2
(ja)
*
|
2015-10-02 |
2022-03-30 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子
|
|
ES2894304T3
(es)
|
2015-10-25 |
2022-02-14 |
Sanofi Sa |
Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH
|
|
CN107207608B
(zh)
*
|
2015-10-30 |
2021-05-11 |
江苏众红生物工程创药研究院有限公司 |
双特异性抗体、其制备方法和用途
|
|
EP3378488A4
(en)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
|
BR112018011029A2
(pt)
|
2016-01-08 |
2018-11-21 |
Hoffmann La Roche |
métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
|
|
AR107582A1
(es)
|
2016-02-03 |
2018-05-16 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
|
|
UA126657C2
(uk)
|
2016-02-03 |
2023-01-11 |
Емджен Рісерч (Мюнік) Ґмбг |
ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
|
|
US11291721B2
(en)
|
2016-03-21 |
2022-04-05 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
JP7015244B2
(ja)
|
2016-03-22 |
2022-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化ｔ細胞二重特異性分子
|
|
WO2017162587A1
(en)
*
|
2016-03-22 |
2017-09-28 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
|
MY192090A
(en)
|
2016-04-13 |
2022-07-26 |
Sanofi Sa |
Trispecific and/or trivalent binding proteins
|
|
EP3443006B1
(en)
*
|
2016-04-13 |
2023-08-02 |
Sanofi |
Trispecific and/or trivalent binding proteins
|
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
|
WO2017194592A1
(en)
|
2016-05-11 |
2017-11-16 |
Ge Healthcare Bioprocess R&D Ab |
Method of storing a separation matrix
|
|
EP3455241B1
(en)
|
2016-05-11 |
2022-02-23 |
Cytiva BioProcess R&D AB |
Method of cleaning and/or sanitizing a separation matrix
|
|
JP7122974B2
(ja)
|
2016-05-11 |
2022-08-22 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
変異免疫グロブリン結合ポリペプチド
|
|
US10730908B2
(en)
|
2016-05-11 |
2020-08-04 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
|
JP7031934B2
(ja)
|
2016-05-11 |
2022-03-08 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
分離マトリックス
|
|
US10654887B2
(en)
|
2016-05-11 |
2020-05-19 |
Ge Healthcare Bio-Process R&D Ab |
Separation matrix
|
|
US10703774B2
(en)
|
2016-09-30 |
2020-07-07 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
|
HRP20251020T1
(hr)
|
2016-05-20 |
2025-10-24 |
Harpoon Therapeutics, Inc. |
Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
|
|
KR102530742B1
(ko)
|
2016-05-20 |
2023-05-09 |
하푼 테라퓨틱스, 인크. |
단일 도메인 혈청 알부민 결합 단백질
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
IL309293A
(en)
*
|
2016-05-23 |
2024-02-01 |
Momenta Pharmaceuticals Inc |
Compositions and methods relating to engineered FC constructs
|
|
US20190233534A1
(en)
|
2016-07-14 |
2019-08-01 |
Fred Hutchinson Cancer Research Center |
Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
|
|
US11312745B2
(en)
|
2016-07-22 |
2022-04-26 |
Amgen Inc. |
Methods of purifying Fc-containing proteins
|
|
EP3511340B1
(en)
|
2016-08-10 |
2024-10-02 |
Ajou University Industry-Academic Cooperation Foundation |
Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
|
|
US12448411B2
(en)
|
2016-09-30 |
2025-10-21 |
Cytiva Bioprocess R&D Ab |
Separation method
|
|
EP3541843A1
(en)
|
2016-11-15 |
2019-09-25 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
JP7215997B2
(ja)
|
2016-11-23 |
2023-01-31 |
ハープーン セラピューティクス，インク． |
前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
|
|
KR102275008B1
(ko)
|
2016-11-23 |
2021-07-13 |
하푼 테라퓨틱스, 인크. |
전립선 특이 막 항원 결합 단백질
|
|
CR20190408A
(es)
|
2017-02-02 |
2020-01-31 |
Amgen Inc |
Composición farmacéutica de bajo ph que comprende construcciones de anticuerpos que activan linfocitos t antecedentes
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
WO2018160754A2
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
MA48763A
(fr)
|
2017-05-05 |
2020-04-08 |
Amgen Inc |
Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
|
|
US10730954B2
(en)
|
2017-05-12 |
2020-08-04 |
Harpoon Therapeutics, Inc. |
MSLN targeting trispecific proteins and methods of use
|
|
SG10202107880XA
(en)
|
2017-05-12 |
2021-09-29 |
Harpoon Therapeutics Inc |
Mesothelin binding proteins
|
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
CA3078969A1
(en)
|
2017-10-13 |
2019-04-18 |
Harpoon Therapeutics, Inc. |
Trispecific proteins and methods of use
|
|
CN111247171A
(zh)
|
2017-10-14 |
2020-06-05 |
西托姆克斯治疗公司 |
抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
|
|
EP3703731A4
(en)
|
2017-11-04 |
2021-07-21 |
Aravive Biologics, Inc. |
METHOD OF TREATMENT OF METASTATIC CANCER USING AXL DECOY RECEPTORS
|
|
AU2018383679C1
(en)
|
2017-12-11 |
2026-05-28 |
Amgen Inc. |
Continuous manufacturing process for bispecific antibody products
|
|
CN111448217A
(zh)
|
2017-12-22 |
2020-07-24 |
阿根思公司 |
双特异性抗原结合构建体
|
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
CR20200391A
(es)
|
2018-02-08 |
2020-10-19 |
Genentech Inc |
Moléculas biespecíficas de unión al antígeno y métodos de uso
|
|
GB201802487D0
(en)
|
2018-02-15 |
2018-04-04 |
Argenx Bvba |
Cytokine combination therapy
|
|
EP3765521A4
(en)
|
2018-03-13 |
2022-03-23 |
Phanes Therapeutics, Inc. |
ANTI-FOLATE RECEPTOR-1 ANTIBODIES AND USES THEREOF
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
US11168138B2
(en)
|
2018-03-26 |
2021-11-09 |
Altor Bioscience, Llc |
Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
|
|
MX2020012217A
(es)
|
2018-05-14 |
2021-03-02 |
Harpoon Therapeutics Inc |
Porción de unión para activación condicional de moléculas de inmunoglobulina.
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
WO2020025532A1
(en)
|
2018-07-30 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
|
|
MX2021001083A
(es)
|
2018-07-31 |
2021-03-31 |
Amgen Res Munich Gmbh |
Regimen posologico para anticuerpos biespecificos contra bcma-cd3.
|
|
BR112021002032A2
(pt)
|
2018-08-03 |
2021-07-20 |
Amgen Research (Munich) Gmbh |
construtos de anticorpos para cldn18.2 e cd3
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN119306844A
(zh)
|
2018-09-25 |
2025-01-14 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
CN113286812B
(zh)
|
2018-09-27 |
2025-05-30 |
西里欧发展公司 |
掩蔽型细胞因子多肽
|
|
BR112021005669A2
(pt)
|
2018-09-28 |
2021-06-22 |
Amgen Inc. |
anticorpos contra bcma solúvel
|
|
MX2021003976A
(es)
|
2018-10-11 |
2021-05-27 |
Amgen Inc |
Procesamiento posterior de constructos de anticuerpos biespecificos.
|
|
DK3870957T3
(da)
|
2018-10-23 |
2025-09-29 |
Amgen Inc |
Automatisk kalibrering og automatisk vedligeholdelse af spectroskopiske modeller til realtidsprediktioner
|
|
KR20210080460A
(ko)
*
|
2018-10-23 |
2021-06-30 |
드래곤플라이 쎄라퓨틱스, 인크. |
이종이량체성 Fc-융합된 단백질
|
|
BR112021008486A2
(pt)
*
|
2018-11-01 |
2021-10-26 |
Shandong New Time Pharmaceutical Co., Ltd |
Anticorpo biespecífico e seu uso
|
|
TWI821474B
(zh)
|
2018-12-07 |
2023-11-11 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Ｃｄ３抗體及其藥物用途
|
|
WO2020136566A1
(en)
|
2018-12-24 |
2020-07-02 |
Sanofi |
Multispecific binding proteins with mutant fab domains
|
|
TWI871300B
(zh)
|
2019-01-28 |
2025-02-01 |
美商安進公司 |
藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
|
|
SG11202109122SA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Anti-tcr antibody molecules and uses thereof
|
|
WO2020172598A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
SG11202109056TA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
JP7579795B2
(ja)
|
2019-02-21 |
2024-11-08 |
マレンゴ・セラピューティクス，インコーポレーテッド |
ＮＫｐ３０に結合する抗体分子およびその使用
|
|
AU2020226893B2
(en)
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
US11613576B2
(en)
|
2019-04-09 |
2023-03-28 |
Sanofi |
Trispecific binding proteins, methods, and uses thereof
|
|
WO2020232303A1
(en)
|
2019-05-14 |
2020-11-19 |
Harpoon Therapeutics, Inc. |
EpCAM BINDING PROTEINS AND METHODS OF USE
|
|
US20220259547A1
(en)
|
2019-06-13 |
2022-08-18 |
Amgeng Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
|
US20220306741A1
(en)
|
2019-09-10 |
2022-09-29 |
Amgen Inc. |
Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
|
|
WO2021091906A1
(en)
|
2019-11-04 |
2021-05-14 |
Amgen Inc. |
Methods for treating leukemia
|
|
HUE068401T2
(hu)
|
2019-11-11 |
2024-12-28 |
Amgen Res Munich Gmbh |
A BCMA elleni hatóanyagok adagolási rendje
|
|
WO2021097344A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
|
CN115916818A
(zh)
|
2019-12-11 |
2023-04-04 |
库利南肿瘤股份有限公司 |
抗cd19抗体和多特异性结合蛋白
|
|
CR20220330A
(es)
|
2019-12-13 |
2022-08-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y métodos de uso.
|
|
IL293640A
(en)
|
2019-12-20 |
2022-08-01 |
Amgen Inc |
CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
|
|
WO2021138474A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
US20230093169A1
(en)
|
2020-01-22 |
2023-03-23 |
Amgen Research (Munch) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
|
WO2021158469A1
(en)
|
2020-02-03 |
2021-08-12 |
Amgen Inc. |
Multivariate bracketing approach for sterile filter validation
|
|
BR112022016550A2
(pt)
|
2020-02-21 |
2022-11-16 |
Harpoon Therapeutics Inc |
Proteínas de ligação a flt3 e métodos de uso
|
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
|
CN115427454A
(zh)
|
2020-03-19 |
2022-12-02 |
安进公司 |
针对粘蛋白17的抗体及其用途
|
|
AU2021261420A1
(en)
|
2020-04-24 |
2022-12-01 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
WO2021236638A1
(en)
|
2020-05-19 |
2021-11-25 |
Amgen Inc. |
Mageb2 binding constructs
|
|
JP2023527972A
(ja)
|
2020-05-29 |
2023-07-03 |
アムジエン・インコーポレーテツド |
Ｃｄ３３及びｃｄ３に結合する二重特異性コンストラクトの有害作用軽減投与
|
|
AU2021304372A1
(en)
|
2020-07-10 |
2023-03-02 |
Biomolecular Holdings Llc |
Tetrahedral antibodies
|
|
TWI915400B
(zh)
*
|
2020-08-14 |
2026-02-21 |
日商中外製藥股份有限公司 |
單臂抗原結合分子及其用途
|
|
CA3190573A1
(en)
|
2020-08-26 |
2022-03-03 |
Andreas Loew |
Methods of detecting trbc1 or trbc2
|
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
JP2023539645A
(ja)
|
2020-08-26 |
2023-09-15 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｎｋｐ３０に結合する抗体分子およびその使用
|
|
WO2022060878A1
(en)
|
2020-09-16 |
2022-03-24 |
Amgen Inc. |
Methods for treating prostate cancer
|
|
AU2021345124A1
(en)
|
2020-09-16 |
2023-03-30 |
Amgen Inc. |
Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
|
|
EP4240493A2
(en)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
JP7716473B2
(ja)
|
2020-11-04 |
2025-07-31 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
|
|
WO2022098638A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
EP4240770A1
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Research (Munich) GmbH |
Polypeptide constructs selectively binding to cldn6 and cd3
|
|
TW202225188A
(zh)
|
2020-11-06 |
2022-07-01 |
德商安美基研究（慕尼黑）公司 |
與ｃｄ３結合的多肽構建體
|
|
AU2021373318A1
(en)
|
2020-11-06 |
2023-05-25 |
Amgen Inc. |
Antigen binding domain with reduced clipping rate
|
|
CA3200317A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
|
US20250136704A1
(en)
|
2020-11-10 |
2025-05-01 |
Amgen Inc. |
Methods for administering a bcmaxcd3 binding molecule
|
|
TW202233684A
(zh)
*
|
2020-11-18 |
2022-09-01 |
美商泰尼歐生物公司 |
結合於葉酸受體α之重鏈抗體
|
|
EP4251187A4
(en)
|
2020-11-25 |
2025-09-10 |
Xilio Dev Inc |
TUMOR-SPECIFIC CLASSIBLE LINKERS
|
|
TW202241935A
(zh)
|
2020-12-18 |
2022-11-01 |
美商世紀治療股份有限公司 |
具有可調適受體專一性之嵌合抗原受體系統
|
|
HUP2100038A1
(hu)
*
|
2021-02-03 |
2022-08-28 |
Richter Gedeon Nyrt |
Mutáltatott rekombináns ACE2-Fc fúziós fehérjék COVID-19 fertõzések kezelésére
|
|
WO2022191971A1
(en)
|
2021-03-10 |
2022-09-15 |
Amgen Inc. |
Parallel chromatography systems and methods
|
|
JP2024509877A
(ja)
|
2021-03-10 |
2024-03-05 |
アムジエン・インコーポレーテツド |
組換えタンパク質の精製方法
|
|
US20250282887A1
(en)
|
2021-04-02 |
2025-09-11 |
Amgen Inc. |
Mageb2 binding constructs
|
|
CA3214757A1
(en)
|
2021-04-08 |
2022-10-13 |
Andreas Loew |
Multifuntional molecules binding to tcr and uses thereof
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
MX2023012931A
(es)
|
2021-05-06 |
2023-11-13 |
Amgen Res Munich Gmbh |
Moleculas de union a antigeno dirigidas a cd20 y cd22 para su uso en enfermedades proliferativas.
|
|
KR20240007171A
(ko)
|
2021-05-14 |
2024-01-16 |
제넨테크, 인크. |
모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
|
|
EP4355778A1
(en)
|
2021-06-17 |
2024-04-24 |
Boehringer Ingelheim International GmbH |
Novel tri-specific binding molecules
|
|
CN113337514B
(zh)
*
|
2021-08-05 |
2021-10-29 |
卡瑞济(北京)生命科技有限公司 |
Tcr表达构建体以及其制备方法和用途
|
|
PE20241343A1
(es)
*
|
2021-10-15 |
2024-07-03 |
Cytomx Therapeutics Inc |
Complejo polipeptidico activable
|
|
WO2023076318A1
(en)
|
2021-10-27 |
2023-05-04 |
Amgen Inc. |
Deep learning-based prediction for monitoring of pharmaceuticals using spectroscopy
|
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
|
TW202334221A
(zh)
|
2021-11-03 |
2023-09-01 |
德商安富美德有限公司 |
雙特異性cd16a結合劑
|
|
US20250084169A1
(en)
|
2022-01-12 |
2025-03-13 |
Biomolecular Holdings Llc |
Nk/monocyte engagers
|
|
JP2025508882A
(ja)
|
2022-02-28 |
2025-04-10 |
エクシリオ デベロップメント， インコーポレイテッド |
標的化サイトカインおよびその使用方法
|
|
WO2023164286A1
(en)
|
2022-02-28 |
2023-08-31 |
Xilio Development, Inc. |
Engineered cd122 compositions and methods thereof
|
|
AU2023268600A1
(en)
|
2022-05-12 |
2024-11-07 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
|
CN119546624A
(zh)
|
2022-07-15 |
2025-02-28 |
西里欧发展公司 |
作为载体的工程化可切割Fc结构域及其使用方法
|
|
AU2023343470A1
(en)
|
2022-09-14 |
2025-02-06 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
|
EP4598958A1
(en)
|
2022-10-05 |
2025-08-13 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
|
AU2024232598A1
(en)
|
2023-03-08 |
2025-07-17 |
Amgen Inc. |
Controlled-ice nucleation lyophilization process for bispecific molecules
|
|
MX2025014635A
(es)
|
2023-06-14 |
2026-02-03 |
Amgen Inc |
Moleculas captadoras de enmascaramiento de celulas t
|
|
WO2025043039A2
(en)
|
2023-08-22 |
2025-02-27 |
Amgen Inc. |
Methods and assemblies for efficiently packing pharmaceutical products
|
|
EP4770754A1
(en)
|
2023-08-30 |
2026-07-08 |
Xilio Development, Inc. |
Vhh masked cytokines and methods of use thereof
|
|
IL326617A
(en)
|
2023-08-30 |
2026-04-01 |
Xilio Dev Inc |
Masked il-2 cytokines and methods of use thereof
|
|
US12698512B2
(en)
|
2023-11-06 |
2026-08-04 |
City Of Hope |
Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers
|
|
WO2025151752A1
(en)
|
2024-01-10 |
2025-07-17 |
Xilio Development, Inc. |
Masked il-2 cytokines and methods of use thereof
|
|
WO2025257588A1
(en)
|
2024-06-10 |
2025-12-18 |
Affimed Gmbh |
Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
|
|
WO2025259515A2
(en)
|
2024-06-11 |
2025-12-18 |
Amgen Inc. |
Combination treatment
|
|
WO2026011013A1
(en)
|
2024-07-02 |
2026-01-08 |
Epibiologics, Inc. |
Binding agents and uses thereof
|
|
WO2026037841A1
(en)
|
2024-08-12 |
2026-02-19 |
ONA Therapeutics S.L. |
Anti-fgfr4 molecules and uses thereof
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
|
WO2026072671A1
(en)
|
2024-09-24 |
2026-04-02 |
City Of Hope |
Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies
|
|
WO2026087751A1
(en)
|
2024-10-24 |
2026-04-30 |
Affimed Gmbh |
Combination of immune cell engager and nk cell products
|
|
EP4751731A1
(en)
|
2024-11-29 |
2026-06-03 |
Affimed GmbH |
Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a taxane
|
|
EP4751734A1
(en)
|
2024-11-29 |
2026-06-03 |
Affimed GmbH |
Bispecific antibody construct dosage regimen for treating nsclc
|
|
EP4751777A1
(en)
|
2024-11-29 |
2026-06-03 |
Affimed GmbH |
Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a vegfr-2 inhibitor
|
|
WO2026136785A1
(en)
|
2024-12-19 |
2026-06-25 |
Amgen Inc. |
T cell engager masking molecules with reduced isomerization tendencies
|
|
CN121971662B
(zh)
*
|
2026-04-03 |
2026-07-14 |
华中科技大学同济医学院附属协和医院 |
一种用于治疗甲状腺癌的载药囊泡及其制备方法和应用
|